We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Olympus

Manufactures optical and digital equipment for the healthcare and consumer electronics sectors, including endoscopy a... read more Featured Products: More products

Download Mobile App




CHI3L1 Protein Differentially Expressed in Appendicitis and Appendix Carcinomas

By LabMedica International staff writers
Posted on 06 Dec 2022
Print article
Image: Olympus Fluoview FV3000 with MPM System, a multispectral, multiphoton laser scanning microscope (Photo courtesy of University Of California, Irvine)
Image: Olympus Fluoview FV3000 with MPM System, a multispectral, multiphoton laser scanning microscope (Photo courtesy of University Of California, Irvine)

Appendicitis is inflammation of the appendix. Symptoms commonly include right lower abdominal pain, nausea, vomiting, and decreased appetite. However, approximately 40% of people do not have these typical symptoms. Adenocarcinoma of the appendix is an epithelial cancer of the appendix.

Chitinase-3-like protein 1 (CHI3L1) is a 40-kDa heparin-and-chitin binding glycoprotein, mainly produced by some cell types, including colonic epithelial cells (CECs) chondrocytes, osteosarcoma cells, macrophages, smooth muscle cells, and neutrophils. High levels of CHI3L1 are associated with poor prognosis and accelerate the proliferation of colon cancer cells.

Clinical Laboratorians at The Affiliated Taian City Central Hospital of Qingdao University (Taian, China) collected blood and appendix samples from 46 acute appendicitis and 14 appendix carcinomas that had surgery at the hospital between May 2019 and November 2021. The patients were divided the acute appendicitis group into acute uncomplicated appendicitis (AUA), suppurative appendicitis (SA), and gangrenous appendicitis (GA). The appendix carcinoma group was divided into appendiceal neuroendocrine neoplasms (ANENs) and appendiceal mucinous neoplasms (AMN). Controls were 32 healthy donors.

The patients' venous blood samples were taken before the appendectomy. Blood neutrophil to lymphocyte ratio (NLR), CHI3L1, C-reactive protein (CRP), interleukin-6 (IL-6, Shenzhen Lifotronic Biotech Co. Ltd, Shenzhen, China), and serum amyloid A (SAA, Upper Bio-TECH Pharma Co. Ltd, Shanghai, China) were measured. NLR was analyzed from a blood routine test. For immunohistochemical staining, sections were rinsed in distilled water three times, and the Quick Antigen Retrieval Solution (Beyotime Biotechnology, Haimen, China) was used for antigen retrieval. Next, 3% bovine serum albumin was used for nonspecific binding blockage, and the sections were incubated with an anti-CHI3L1 antibody at 4° C overnight. Fluorescence images were obtained using an Olympus FV3000 confocal microscope (Olympus, Center Valley, Pa, USA).

The investigators reported that compared with the controls, CHI3L1 serum levels were up-regulated in SA, GA, and AMN groups, while no significant difference was observed in the AUA and ANEN groups. Immunofluorescence revealed that CHI3L1 expression was high in macrophages and adenocarcinoma cells of appendix tissues, but not in the neuroendocrine carcinoma tissues. Moreover, levels of NLR and CRP in the SA and GA groups were considerably higher than in the control group. IL-6 and SAA in SA, GA, ANENs, and AMN groups were also increased compared with the control group. In addition, CHI3L1 displayed good performance in predicting appendicitis, with an AUC of 0.862.

The authors concluded that the patients with appendicitis had an enhanced CHI3L1 expression, associated with increased NLR, CRP, IL-6, and SAA. Moreover, CHI3L1 was crucial in patients with appendiceal neuroendocrine neoplasms. The study was published on November 29, 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:
The Affiliated Taian City Central Hospital of Qingdao University
Shenzhen Lifotronic Biotech Co. Ltd
Upper Bio-TECH Pharma Co. Ltd
Beyotime Biotechnology
Olympus

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Automatic ELISA Workstation
URANUS AE65

Print article

Channels

Molecular Diagnostics

view channel
Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)

Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection

Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.